Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Musculoskeletal
Disease Category: Leukemia
Location: United States, IL
Clinical Trial Details
Research Study Summary
E2906 - Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age>/=60 Years
This is a clinical trial, a type of research study. Your doctor will explain the clinical trial to you. Clinical trials include only people who choose to participate. Please take your time to make your decision about participating. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your doctor for more explanation.
WHY IS THIS STUDY BEING DONE?
You are being asked to participate in this study because you are over 60 years old and have been recently diagnosed with acute myeloid leukemia (AML).
This study is being done to determine which treatment is best for older patients with newly diagnosed AML.
Patient Inclusion Criteria:
- Age ≥ 60 years
- Sexually active males must be strongly advised to use an accepted and effective method of contraception.
Patient Exclusion Criteria:
- Patient must not have a concurrent active malignancy for which they are receiving treatment (other than MDS)
- Patient must not have an active, uncontrolled infection.
To Learn more
Both Male and Female
Date Last Changed:
July 17, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these